IANS | Feb 19, 2021, 3:58 PM IST
The petitioner has demanded an interim injunction on the administration of Covishield to the public and a compensation of Rs 5 crore for the damages he incurred after undergoing the vaccine trial.
IANS | Feb 13, 2021, 5:58 PM IST
This trial will assess if children and young adults aged 6-17 years develop a good immune response with the ChAdOx1 nCoV-19 vaccine.
India.com News Desk | Feb 3, 2021, 5:23 PM IST
The Oxford study raises hope among people as its AstraZeneca vaccine can cut coronavirus transmissions by around 67 per cent and thus can control the spread of the deadly virus.
India.com News Desk | Jan 5, 2021, 11:29 AM IST
The largest Latin American nation has also struck a preliminary deal with Bharat Biotech despite a lack of public results from late-stage trials.
India.com News Desk | Jan 4, 2021, 1:33 PM IST
The national drugs regulator DCGI on Sunday approved Bharat Biotech's Covaxin and Oxford-Serum's Covishield, for restricted emergency use in the country, paving the way for a massive inoculation drive.
PTI | Jan 4, 2021, 2:15 PM IST
This is a major milestone in the phased vaccination programme being undertaken in the UK as the Oxford jab became the second vaccine approved for rollout after the Pfizer/BioNTech vaccine.
India.com News Desk | Jan 4, 2021, 12:12 AM IST
"We will never approve anything if there is even the slightest safety concern. Vaccines are 110 per cent safe. Some side effects like mild fever, pain and allergy are common for every vaccine," DCGI V G Somani told the media here. His assertion came after a few raised concerns over the safety of the vaccines.
India.com News Desk | Dec 27, 2020, 5:11 PM IST
The oxford Coronavirus vaccine is likely to be cleared by the British drug regulator this week. Soriot also exuded confidence that the drug will be affective against the mutated strain of Coronavirus too.
India.com News Desk | Dec 23, 2020, 8:53 AM IST
Coronavirus Vaccine Update: The government committee for vaccine approval is currently going through applications of at least three firms that have sought for emergency use in India.
India.com News Desk | Dec 7, 2020, 10:11 AM IST
Coronavirus Vaccine Update: While both Pfizer and Oxford vaccines have shown promising results in phase 3 clinical trials, one of them is likely to cost more than the other.
India.com News Desk | Dec 7, 2020, 7:27 AM IST
Coronavirus Vaccine Update: Citing reasons, the SII said the vaccine was necessary for "unmet medical needs due to the pandemic" and "interest of the public at large".
India.com News Desk | Dec 3, 2020, 7:12 AM IST
AstraZeneca had briefly paused its study in the vaccine trials in th US in October after a report of a serious neurological illness in a participant in the UK.
English
